Changing microRNA's Presence in Glioblastoma Cells Could Change the Tumor's Subtype
Credit: Lee Health Vimeo Channel
Glioblastoma multiforme (GBM), an extremely aggressive brain cancer, is a very complex disease. It is characterized by a fast-growing tumor in the brain composed of many subpopulations of cells, including glioblastoma stem cells, which play a crucial role in glioblastoma initiation, expansion and therapy-resistance. GBM's diverse make up -- termed heterogeneity -- is of clinical importance because it is a key factor that leads to treatment failure, allowing the tumor to become resistant to treatment or for cancer to recur.
One way to identify different glioblastoma subtypes is by looking at the specific microRNA expressed in the patient derived GBM stem cells. In several types of cancer cells, including glioblastoma cells, microRNA expression isn't regulated properly. In a new study published in Cell Reports, BWH researchers examined a specific microRNA, miR-128, to help identify glioblastoma subtypes and to determine if altering the microRNA's presence in glioblastoma cells could change the tumor's subtype.
"RNA is increasingly recognized as a snapshot of a cell at a given moment in time and therefore gives unique insight into the disease biology," said lead author Arun Kumar Rooj, PhD, of the Department of Neurosurgery at BWH. "Understanding the dynamic spectrum of cells and their non-coding RNA signatures is critical for advancing therapeutic strategies that will be capable of overcoming the complexity of this disease."
The researchers looked at miR-128 expression in diverse populations of glioblastoma cells. They identified the "proneural" subtype as having high levels of miR-128 compared to the mesenchymal tumors, which had significantly lower levels of this particular microRNA. Interestingly, they also found that if they raised or lowered the levels of miR-128, they could induce one subtype of tumor to transition into a new subtype.
"Mesenchymal glioblastoma is extremely aggressive, highly heterogeneous and has the poorest chance of survival for patients," said corresponding author Agnieszka Bronisz, PhD, of the BWH Department of Neurosurgery. "By altering the level of miR-128 in both mesenchymal and proneural tumors, we can shift the tumor into a more hybrid type, similar to the "classical" subtype which is more homogenous and easier to treat."
"The ability to transform more aggressive types of glioblastoma into a subtype that is more responsive to treatment opens the door for using miR-128 as a therapeutic agent," said corresponding author Jakub Godlewski, PhD, of the BWH Department of Neurosurgery.
This article has been republished from materials provided by Brigham and Women's Hospital. Note: material may have been edited for length and content. For further information, please contact the cited source.
Arun K. Rooj, Franz Ricklefs, Marco Mineo, Ichiro Nakano, E. Antonio Chiocca, Agnieszka Bronisz, Jakub Godlewski. MicroRNA-Mediated Dynamic Bidirectional Shift between the Subclasses of Glioblastoma Stem-like Cells. Cell Reports, 2017; 19 (10): 2026 DOI: 10.1016/j.celrep.2017.05.040
Duplicate Genes Offer a Explanation for Differences Between the SexesNews
A study in flies has identified the process by duplicating a gene can help resolve genetic sexual conflict.READ MORE
Pre-Clinical Safety in Cancer Drug Development: “Attitude to Safety Needs to Change”News
Many companies involved in cancer drug research and development need to re-think their use of safety data in helping to bring new drugs to cancer patients.
Dr Richard Knight of ApconiX will tell this month’s conference, that greater focus on pre-clinical safety should be fundamental to the development of new cancer therapies.
Understanding the Process of Cell DivisionNews
Using multiple techniques such as structural modelling, X-ray scattering, X-ray crystallography and electron microscopy, scientists have found that the Spc110 protein provides a greater function in mitosis originally believed. This information could help understand the process in human cells and the abnormalities that occur in cancer.READ MORE